• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mobile Compression Reduces Bleeding-related Readmissions and Wound Complications After THA and TKA.移动加压可减少全髋关节置换术(THA)和全膝关节置换术(TKA)后与出血相关的再入院率及伤口并发症。
Clin Orthop Relat Res. 2018 Feb;476(2):381-387. doi: 10.1007/s11999.0000000000000041.
2
No Difference Between Low- and Regular-dose Aspirin for Venous Thromboembolism Prophylaxis After THA.低剂量与常规剂量阿司匹林用于全髋关节置换术后静脉血栓栓塞症预防的效果无差异。
Clin Orthop Relat Res. 2019 Feb;477(2):396-402. doi: 10.1097/CORR.0000000000000613.
3
Bleeding and thromboembolism risk of standard antithrombotic prophylaxis after hip or knee replacement within an enhanced recovery program.在强化康复方案中,髋关节或膝关节置换术后标准抗血栓预防的出血和血栓栓塞风险。
Orthop Traumatol Surg Res. 2020 Dec;106(8):1533-1538. doi: 10.1016/j.otsr.2020.02.026. Epub 2020 Oct 28.
4
Pharmacological thromboprophylaxis and its impact on venous thromboembolism following total knee and hip arthroplasty in Korea: A nationwide population-based study.韩国全膝关节和全髋关节置换术后的药物性血栓预防及其对静脉血栓栓塞的影响:一项基于全国人口的研究。
PLoS One. 2017 May 24;12(5):e0178214. doi: 10.1371/journal.pone.0178214. eCollection 2017.
5
Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.Xa 因子抑制剂和直接凝血酶抑制剂与低分子肝素在全髋关节或全膝关节置换术后预防血栓形成的比较:系统评价和荟萃分析。
J Arthroplasty. 2019 Apr;34(4):789-800.e6. doi: 10.1016/j.arth.2018.11.029. Epub 2018 Dec 1.
6
Staged venous thromboemolic events prophylaxis with low-molecular-weight heparin followed by aspirin is safe and effective after arthroplasty.关节置换术后,采用低分子量肝素序贯阿司匹林进行静脉血栓栓塞事件预防是安全有效的。
ANZ J Surg. 2015 Sep;85(9):652-7. doi: 10.1111/ans.13174. Epub 2015 May 21.
7
Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.低分子量肝素与其他抗血栓药物用于预防全髋关节或全膝关节置换术后静脉血栓栓塞事件:一项系统评价和荟萃分析。
BMC Musculoskelet Disord. 2018 Sep 8;19(1):322. doi: 10.1186/s12891-018-2215-3.
8
Comparison of 90-Day Adverse Events Associated With Aspirin and Potent Anticoagulation Use for Venous Thromboembolism Prophylaxis: A Cohort Study of 72,288 Total Knee and 35,142 Total Hip Arthroplasty Patients.比较阿司匹林与强效抗凝药物用于静脉血栓栓塞症预防的 90 天不良事件:72288 例全膝关节置换和 35142 例全髋关节置换患者的队列研究。
J Arthroplasty. 2023 Aug;38(8):1602-1612.e1. doi: 10.1016/j.arth.2023.02.021. Epub 2023 Feb 18.
9
Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.低分子量肝素或利伐沙班预防髋膝关节置换术后血栓栓塞的疗效和安全性:来自 ORTHO-TEP 注册研究的结果。
Thromb Haemost. 2013 Jan;109(1):154-63. doi: 10.1160/TH12-07-0510. Epub 2012 Nov 29.
10
Similar Clinical Outcomes with Preoperative and Postoperative Start of Thromboprophylaxis in THA: A Register-based Study.全髋关节置换术中术前与术后开始血栓预防的相似临床结局:一项基于登记的研究
Clin Orthop Relat Res. 2017 Sep;475(9):2245-2252. doi: 10.1007/s11999-017-5419-1. Epub 2017 Jun 22.

引用本文的文献

1
Safety and efficacy of personalised delayed anticoagulation for reducing perioperative blood loss in total knee arthroplasty patients: protocol for a randomised controlled trial.个性化延迟抗凝在减少全膝关节置换术患者围手术期失血中的安全性和有效性:一项随机对照试验方案
BMJ Open. 2025 Sep 9;15(9):e092640. doi: 10.1136/bmjopen-2024-092640.
2
Personalized delayed anticoagulation therapy alleviates postoperative bleeding in total knee arthroplasty (TKA) patients.个性化延迟抗凝治疗可减轻全膝关节置换术(TKA)患者的术后出血。
J Exp Orthop. 2024 Oct 30;11(4):e70074. doi: 10.1002/jeo2.70074. eCollection 2024 Oct.
3
The Role of Anti-Factor Xa Activity in the Management of Ecchymosis in Patients Receiving Rivaroxaban after Total Knee Arthroplasty.抗Xa因子活性在全膝关节置换术后接受利伐沙班治疗的患者瘀斑管理中的作用
J Clin Med. 2023 Feb 1;12(3):1161. doi: 10.3390/jcm12031161.
4
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.与依诺肝素相比,膝关节置换术后使用单侧气动装置进行血栓预防可导致更少的水肿和出血:随机试验。
BMC Musculoskelet Disord. 2022 Nov 15;23(1):984. doi: 10.1186/s12891-022-05910-9.
5
Asia-Pacific venous thromboembolism consensus in knee and hip arthroplasty and hip fracture surgery: Part 2. Mechanical venous thromboembolism prophylaxis.《亚太地区膝关节和髋关节置换术及髋部骨折手术静脉血栓栓塞共识:第2部分。机械性静脉血栓栓塞预防》
Knee Surg Relat Res. 2021 Jun 30;33(1):20. doi: 10.1186/s43019-021-00101-7.
6
Ambulatory Portable Pneumatic Compression Device as Part of a Multimodal Aspirin-Based Approach in Prevention of Venous Thromboembolism in Outpatient Total Knee Arthroplasty.门诊便携式气动压缩装置作为基于阿司匹林的多模式方法的一部分,用于预防门诊全膝关节置换术中的静脉血栓栓塞。
Arthroplast Today. 2020 Jun 16;6(3):378-380. doi: 10.1016/j.artd.2020.05.007. eCollection 2020 Sep.
7
Blood management in fast-track orthopedic surgery: an evidence-based narrative review.快速骨科手术中的血液管理:基于循证的叙述性综述。
J Orthop Surg Res. 2019 Aug 20;14(1):263. doi: 10.1186/s13018-019-1296-5.

本文引用的文献

1
Traumatic Brain Injury Severity, Comorbidity, Social Support, Family Functioning, and Community Reintegration Among Veterans of the Afghanistan and Iraq Wars.阿富汗和伊拉克战争退伍军人的创伤性脑损伤严重程度、合并症、社会支持、家庭功能和社区重新融入。
Arch Phys Med Rehabil. 2018 Feb;99(2S):S40-S49. doi: 10.1016/j.apmr.2017.05.021. Epub 2017 Jun 23.
2
Gambling in a National U.S. Veteran Population: Prevalence, Socio-demographics, and Psychiatric Comorbidities.美国退伍军人中的赌博行为:患病率、社会人口统计学特征及精神疾病共病情况
J Gambl Stud. 2017 Dec;33(4):1099-1120. doi: 10.1007/s10899-017-9678-2.
3
Incidences of Deep Vein Thrombosis and Pulmonary Embolism after Total Knee Arthroplasty Using a Mechanical Compression Device with and without Low-Molecular-Weight Heparin.使用或不使用低分子量肝素的机械压迫装置行全膝关节置换术后深静脉血栓形成和肺栓塞的发生率
Knee Surg Relat Res. 2016 Sep;28(3):213-8. doi: 10.5792/ksrr.2016.28.3.213. Epub 2016 Aug 25.
4
The Effectiveness of a Risk Stratification Protocol for Thromboembolism Prophylaxis After Hip and Knee Arthroplasty.髋膝关节置换术后血栓栓塞预防风险分层方案的有效性
J Arthroplasty. 2016 Jun;31(6):1299-1306. doi: 10.1016/j.arth.2015.12.007. Epub 2015 Dec 17.
5
Serious mental illnesses associated with receipt of surgery in retrospective analysis of patients in the Veterans Health Administration.在退伍军人健康管理局患者的回顾性分析中,与接受手术相关的严重精神疾病。
BMC Surg. 2015 Jun 18;15:74. doi: 10.1186/s12893-015-0064-7.
6
A mobile compression device for thrombosis prevention in hip and knee arthroplasty.一种用于髋关节和膝关节置换术预防血栓的移动压缩装置。
J Bone Joint Surg Am. 2014 Feb 5;96(3):177-83. doi: 10.2106/JBJS.L.01031.
7
Complications related to therapeutic anticoagulation in total hip arthroplasty.全髋关节置换术治疗性抗凝相关并发症。
J Arthroplasty. 2013 Jan;28(1):187-92. doi: 10.1016/j.arth.2012.06.001.
8
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.达比加群、利伐沙班或阿哌沙班与依诺肝素预防全髋关节或膝关节置换术后血栓形成的比较:系统评价、荟萃分析和间接治疗比较。
BMJ. 2012 Jun 14;344:e3675. doi: 10.1136/bmj.e3675.
9
Cost-effectiveness of venous thromboembolism prophylaxis with a new mobile device after total hip arthroplasty.新型移动设备在全髋关节置换术后预防静脉血栓栓塞症的成本效益。
J Arthroplasty. 2012 Sep;27(8):1513-1517.e1. doi: 10.1016/j.arth.2012.03.024. Epub 2012 May 21.
10
American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty.美国矫形外科医师学会关于择期髋关节和膝关节置换术患者预防静脉血栓栓塞性疾病的临床实践指南。
J Bone Joint Surg Am. 2012 Apr 18;94(8):746-7. doi: 10.2106/JBJS.9408.ebo746.

移动加压可减少全髋关节置换术(THA)和全膝关节置换术(TKA)后与出血相关的再入院率及伤口并发症。

Mobile Compression Reduces Bleeding-related Readmissions and Wound Complications After THA and TKA.

作者信息

Arsoy Diren, Giori Nicholas J, Woolson Steven T

机构信息

Department of Orthopaedic Surgery, Stanford University, Stanford, CA, USA; and VA Palo Alto Health Care System, Palo Alto, CA, USA.

出版信息

Clin Orthop Relat Res. 2018 Feb;476(2):381-387. doi: 10.1007/s11999.0000000000000041.

DOI:10.1007/s11999.0000000000000041
PMID:29529673
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6259721/
Abstract

BACKGROUND

The use of chemoprophylaxis to prevent thromboembolic disease after primary THA and TKA can be associated with postoperative bleeding complications. Mechanical prophylaxis has been studied as an alternative to chemoprophylaxis with greater safety in patients undergoing THA, but no data have been published comparing the safety of chemoprophylaxis versus mechanical methods for patients undergoing TKA. The risk of readmission resulting from bleeding and venous thromboembolism (VTE) has also not been determined for patients undergoing THA or TKA when treated with low-molecular-weight heparin (LMWH) alone compared with mechanical prophylaxis plus aspirin (ASA).

QUESTION/PURPOSES: We sought to answer four questions: For the THA and TKA cohorts, respectively, (1) was the incidence of readmission resulting from VTE and bleeding complications higher with LMWH than mobile compression plus ASA; and (2) was the incidence of wound bleeding complications higher with LMWH than mechanical compression plus ASA? For the TKA cohort specifically, (3) was the frequency of systemic bleeding events and complications related to chemical prophylaxis higher with LMWH compared with mechanical compression plus ASA? (4) Was there a difference in symptomatic VTEs between LMWH and mechanical compression plus ASA?

METHODS

Between November 2008 and April 2011, 632 patients underwent primary THA and TKA. Seventy-two patients (11%) were identified before surgery as being at high risk for VTE (31 patients) or bleeding (41 patients) and were excluded from the study. Five hundred sixty patients (89%) were considered to be at standard risk for VTE and bleeding and comprise the study cohort. Between November 2008 and November 2009, 252 patients (76 THAs, 176 TKAs) underwent THA and TKA and were treated with LMWH (5 mg dalteparin given subcutaneously daily for 14 days) and in-hospital nonmobile mechanical compression. Between November 2009 and April 2011, a total of 308 patients undergoing THA and TKA (108 THAs, 200 TKAs) were treated using a mobile compression device plus oral aspirin once daily for 2 weeks after surgery. All complications and readmissions that occurred within 6 weeks of surgery were noted. There were no differences between the VTE treatment groups with regard to age, sex, or body mass index.

RESULTS

For the THA cohort, there was no difference in the frequency of readmission for a bleeding complication (wound or systemic) between the two groups (2.6% for LMWH versus 0.9% for mobile compression; p = 0.57; odds ratio [OR], 2.9). Patients undergoing TKA treated with LMWH had higher readmission rates within 6 weeks of surgery because of a bleeding complication, a wound infection, or the development of a VTE (6.8% for LMWH versus 1.5% for mobile compression; p = 0.015; OR, 4.8). For the THA cohort, there was higher wound bleeding complication frequency with LMWH (9.2% for LMWH versus 0.9% for mechanical compression; p = 0.009; OR, 10.9). Patients undergoing TKA treated with LMWH had a higher frequency of wound bleeding complications or infection (3.9% for LMWH versus 0.5% for mobile compression; p = 0.028; OR, 8.2). Patients undergoing TKA treated with LMWH had higher rates of systemic bleeding or a complication secondary to LMWH administration (2.8% for LMWH versus 0% for mobile compression; p = 0.022; OR, 12.8). No difference was noted in the rate of symptomatic VTEs between either group (for THA: 2.6% for the LMWH group versus 1.9% for the mechanical compression group; p = 1; for TKA: 1.1% versus 0%, respectively; p = 0.22).

CONCLUSIONS

Based on these results, we advocate for routine use of mobile mechanical compression devices in the prevention of VTEs and complications associated with more potent chemical anticoagulants. However, more focused randomized clinical trials are needed to validate these findings.

LEVEL OF EVIDENCE

Level III, therapeutic study.

摘要

背景

在初次全髋关节置换术(THA)和全膝关节置换术(TKA)后使用化学预防措施预防血栓栓塞性疾病可能会伴有术后出血并发症。在接受THA的患者中,机械预防措施作为化学预防的替代方法已被研究,且安全性更高,但尚无关于TKA患者化学预防与机械方法安全性比较的数据发表。对于接受THA或TKA的患者,单独使用低分子量肝素(LMWH)与机械预防加阿司匹林(ASA)相比,因出血和静脉血栓栓塞(VTE)导致再入院的风险也尚未确定。

问题/目的:我们试图回答四个问题:分别针对THA和TKA队列,(1)LMWH组因VTE和出血并发症导致的再入院发生率是否高于可移动压迫加ASA组;(2)LMWH组伤口出血并发症的发生率是否高于机械压迫加ASA组?专门针对TKA队列,(3)与机械压迫加ASA相比,LMWH组全身出血事件及与化学预防相关并发症的发生频率是否更高?(4)LMWH组与机械压迫加ASA组在有症状VTE方面是否存在差异?

方法

2008年11月至2011年4月期间,632例患者接受了初次THA和TKA手术。72例患者(11%)在手术前被确定为VTE(31例)或出血(41例)高风险患者,并被排除在研究之外。560例患者(89%)被认为是VTE和出血的标准风险患者,构成研究队列。2008年11月至2009年11月期间,252例患者(76例THA,176例TKA)接受了THA和TKA手术,并接受LMWH治疗(每天皮下注射5mg达肝素,共14天)及院内非可移动机械压迫。2009年11月至2011年4月期间,共有308例接受THA和TKA手术的患者(108例THA,200例TKA)在术后使用可移动压迫装置加口服阿司匹林,每日一次,共2周。记录了术后6周内发生的所有并发症和再入院情况。VTE治疗组在年龄、性别或体重指数方面无差异。

结果

对于THA队列,两组因出血并发症(伤口或全身)导致的再入院频率无差异(LMWH组为2.6%,可移动压迫组为0.9%;p = 0.57;比值比[OR],2.9)。接受LMWH治疗的TKA患者在术后6周内因出血并发症、伤口感染或VTE发生的再入院率更高(LMWH组为6.8%,可移动压迫组为1.5%;p = 0.015;OR,4.8)。对于THA队列,LMWH组伤口出血并发症频率更高(LMWH组为9.2%,机械压迫组为0.9%;p = 0.009;OR,10.9)。接受LMWH治疗的TKA患者伤口出血并发症或感染的频率更高(LMWH组为3.9%,可移动压迫组为0.5%;p = 0.028;OR,8.2)。接受LMWH治疗的TKA患者全身出血或LMWH给药继发并发症的发生率更高(LMWH组为2.8%,可移动压迫组为0%;p = 0.022;OR,12.8)。两组间有症状VTE的发生率无差异(对于THA:LMWH组为2.6%,机械压迫组为1.9%;p = 1;对于TKA:分别为1.1%和0%;p = 0.22)。

结论

基于这些结果,我们主张常规使用可移动机械压迫装置预防VTE及与更强效化学抗凝剂相关的并发症。然而,需要更有针对性的随机临床试验来验证这些发现。

证据水平

III级,治疗性研究。